Immune checkpoint blockade therapy using anti-PD-1 or PD-L1 antibodies in cancer patients has been associated with autoimmune-like adverse effects, although the underlying mechanisms remain poorly understood40,41. This evidence concerns the gene PDCD1 and cancer.